Get the Stockscreener App
11.46
6.70%
0.72
Kailera Therapeutics Inc stock is traded at $11.46, with a volume of 530.32K.
It is up +6.70% in the last 24 hours and down -14.80% over the past month.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
See More
Previous Close:
$10.74
Open:
$10.61
24h Volume:
530.32K
Relative Volume:
0.35
Market Cap:
$1.49B
Revenue:
Net Income/Loss:
P/E Ratio:
-18.83
EPS:
-0.6087
Net Cash Flow:
1W Performance:
+14.60%
1M Performance:
-14.80%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.50
$11.49
1-Week Range:
$9.98
$11.81
52-Week Range:
$9.76
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Name
Kailera Therapeutics Inc
Sector
Industry
Phone
508-440-9475
Address
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
11.46 | 1.49B | 0 | 0 | 0 | -0.6087 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-26 | Initiated | Evercore ISI | Outperform |
| May-12-26 | Initiated | JP Morgan | Overweight |
| May-12-26 | Initiated | Jefferies | Buy |
| May-12-26 | Initiated | Leerink Partners | Outperform |
| May-12-26 | Initiated | TD Cowen | Buy |
| May-12-26 | Initiated | William Blair | Outperform |
View All
Kailera Therapeutics Inc Stock (KLRA) Latest News
Kailera Therapeutics (Nasdaq:KLRA)Stock Analysis - Simply Wall Street
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation (KLRA) - Seeking Alpha
Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week LowWhat's Next? - MarketBeat
Kailera Therapeutics (KLRA) grants CTO 220,000 stock options - stocktitan.net
Kailera Therapeutics (KLRA) CTO reports no shares in first ownership filing - Stock Titan
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7%Should You Sell? - MarketBeat
Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA - MarketBeat
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA - MarketBeat
2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9%Here's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Kailera Stock Falls 12.5%, Leaving Market Value Just $930 Million Above Cash - TechStock²
Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6%Should You Sell? - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading 8.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year LowHere's Why - MarketBeat
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hengrui Pharma's Innovative Drug Revenue Share Tops 60% in H1; Two NewCo Partners List on Nasdaq - finance.biggo.com
2 GLP-1 Stocks That Could Double Your Money by 2031 - AOL.com
KLRA Archives - 24/7 Wall St.
KLRA Archives - 24/7 Wall St.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - 24/7 Wall St.
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - Yahoo Finance
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? - Yahoo Finance
2 GLP-1 Stocks That Could Double Your Money by 2031 - The Motley Fool
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - stocktitan.net
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
KLRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Q2 loss widens 285% to $111.3M on R&D surge; cash runway extends to mid-2028 - scanx.trade
Kailera Therapeutics Submits Q2 2026 10-Q Highlighting Financial Status and Operational Risks - Kalkine Media
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Australia
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Nigeria
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com Canada
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com India
Kailera Therapeutics, Inc. 2Q 2026: Revenue N/A, Net loss $(111.3M), EPS $(1.09) — 10-Q Summary - TradingView
KLRA: Q2 net loss rose to $111.3M on higher R&D; $1.17B cash post-IPO funds operations into mid-2028 - tradingview.com
Form 8K Kailera Therapeutics For: 12 August By Investing.com - Investing.com UK
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings | KLRA Stock News - Quiver Quantitative
Kailera Therapeutics, Inc. Announces Appointment of Nur Nicholson as Chief Technology Officer, Effective August 31, 2026 - marketscreener.com
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - The Manila Times
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer - GlobeNewswire
Kailera Therapeutics Inc Stock (KLRA) Financials Data
There is no financial data for Kailera Therapeutics Inc (KLRA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Kailera Therapeutics Inc Stock (KLRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
500,000 |
8,000,000 |
10,776,820 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):